The adverse events resulting from the combined use of PD-L1 inhibitors and platinum-based doublet chemotherapy cannot be ignored.[5] Notably, in recent years, platinum chemotherapy has been used as the first-line therapy for advanced NSCLC patients without target-driven gene mutations,[27] but the problem of the high incidence of adverse reactions is difficult to address.[28] PD-L1 inhibitors when used in combination chemotherapy result in serious side effects and high drug withdrawal rate. The gene discussed is CD274; the disease is non-small cell lung carcinoma.